The DEA Just Made HHC a Schedule I Drug. Midwest Smoke Shops Are in the Crossfire.

On May 4, the Drug Enforcement Administration quietly dropped one of the most consequential actions in hemp retail history: it assigned hexahydrocannabinol — better known as HHC — its own Schedule I drug code, formalizing the federal government’s long-held but rarely tested position that the synthetic cannabinoid is illegal under the Controlled Substances Act.

For the Midwest, where HHC vapes and gummies became a fixture behind smoke shop counters from the South Side of Chicago to the college towns of Ann Arbor and Columbia, Missouri, the move is not a surprise. It is a reckoning that many in the industry saw coming and few were adequately prepared for.

What the DEA Did — and Why It Matters

Assigning a Schedule I drug code to HHC does not, by itself, create a new law. HHC’s legal status has been contested for years, caught in the grey zone created by the 2018 Farm Bill’s legalization of hemp and its derivatives. The DEA’s position has consistently been that cannabinoids synthesized from CBD — including HHC — fall outside the Farm Bill’s protection because they are not naturally occurring in meaningful concentrations. In the agency’s view, HHC was always illegal.

What the new drug code does is operationalize that position. Federal prosecutors, customs agents, and state-level enforcement agencies now have a specific statutory hook to hang charges on. The grey zone that HHC retailers have operated in for the better part of four years just got measurably smaller.

The timing is notable. It comes just days after the Trump administration’s April 23 rescheduling order moved state-licensed medical cannabis to Schedule III — a move framed as progress for the legal cannabis industry. The juxtaposition reveals an emerging two-track federal posture: regulated, licensed cannabis operators get incremental relief; unregulated hemp-derived intoxicants get the hammer.

The Midwest’s HHC Economy Is Not Trivial

To understand the stakes here, you need to understand how deeply HHC embedded itself into the Midwest’s hemp retail infrastructure over the past three years.

Illinois legalized adult-use cannabis in 2020, but recreational cannabis is expensive, licensed, and taxed. The licensed dispensary down the street from a smoke shop can charge $60 for an eighth. The smoke shop’s HHC gummies offer a similar experience — in the eyes of consumers, at least — for a fraction of the price and without the dispensary’s regulatory overhead. That price gap drove an enormous parallel market.

In Michigan, where the legal cannabis market is the most competitive and price-compressed in the country, HHC carved out space in the same sub-economy: gas stations, vape stores, head shops, and convenience retailers that could not or chose not to pursue cannabis licenses. The same pattern holds across Ohio, Minnesota, Indiana, Missouri, Iowa, and Wisconsin — states with varying levels of cannabis access where hemp-derived cannabinoids filled the gaps.

Industry observers have estimated that HHC and similar synthetic hemp cannabinoids generated hundreds of millions of dollars annually in retail sales at their peak. The Midwest, with its dense network of independent smoke shops and lower-overhead hemp retailers, captured a meaningful share of that.

Legal Fights Already Underway

The DEA has been here before, and it has lost.

Federal appeals courts have ruled against the agency on structurally similar hemp-derived cannabinoids. Delta-8 THC — the synthetic cannabinoid that preceded HHC in the market — survived multiple court challenges in part because judges found that the Farm Bill’s plain language protected any hemp derivative with less than 0.3% delta-9 THC, regardless of the production process involved. The Ninth and other circuits have generally not deferred to the DEA’s interpretation when it conflicts with the Farm Bill’s text.

HHC’s defenders will make the same argument. The question is whether courts continue to draw the line at the Farm Bill’s delta-9 THC threshold, or whether judges begin accepting the DEA’s broader theory that chemically synthesized cannabinoids — regardless of source material — are per se illegal under the analogue provisions of the Controlled Substances Act.

That legal battle will play out over years. In the meantime, Midwest retailers face a more immediate problem: what do they do with existing inventory, and what do they tell customers who have been buying HHC products legally — or what felt like legally — for years?

State Law Is Not a Safe Harbor Anymore

Several Midwest states had already moved to regulate or restrict hemp-derived intoxicants ahead of this DEA action. Minnesota passed legislation in 2023 creating an explicit regulatory framework for edibles and beverages containing hemp-derived THC — one of the first states to do so. Illinois has grappled with how to treat hemp-derived cannabinoids in light of its existing adult-use framework. Michigan’s regulators have been wrestling with the issue for two years.

But state-level permissive frameworks do not insulate retailers from federal enforcement, and the DEA’s scheduling action makes federal prosecution a real, rather than theoretical, risk. A retailer operating in full compliance with Minnesota’s hemp edibles rules can still face federal charges if prosecutors want to bring them.

That risk calculus is about to change for a lot of Midwest shop owners who have been watching the situation and hoping the legal environment would clarify in their favor before federal enforcement arrived.

The Trump Signal Is Mixed

The broader political context adds another layer of complexity. President Trump has been publicly supportive of hemp, recently calling on Congress to loosen federal restrictions on hemp-derived CBD and other cannabinoids — a signal that read, to many in the industry, as favorable for the hemp sector broadly.

But there is a meaningful distinction between CBD, which has no intoxicating properties and enjoys broad consumer acceptance, and HHC, which is an intoxicant that consumers use to get high. The Trump administration appears to be drawing that line sharply: unlock hemp’s wellness and agricultural potential, crack down on the intoxicating synthetic cannabinoid market that has grown up in its shadow.

For Midwest retailers, that distinction matters enormously. CBD products remain safe. HHC just got a lot riskier.

What Comes Next

The immediate practical question is enforcement priority. The DEA’s drug code assignment sets the legal foundation; it does not guarantee an enforcement surge. Federal agencies routinely prioritize resources, and a nationwide crackdown on smoke shop HHC inventory is not imminent simply because a scheduling action was published.

What it does do is expose every HHC retailer in Illinois, Michigan, Ohio, and across the Midwest to a risk they cannot paper over with a Farm Bill compliance argument anymore — at least not until the courts weigh in again. Attorneys representing hemp retailers are already advising clients to consult with counsel before the next restock order.

The legal cannabis operators who have been watching HHC eat into their market share are watching this development with something approaching satisfaction. They went through licensing, testing, taxes, and compliance to operate in a regulated market. The pressure is now, finally, coming for the product that undercut them.

Whether that pressure produces a level playing field — or just a smaller market overall — depends on what courts and Congress do next.

Marcus Okafor covers Midwest cannabis policy and markets for CannabisInquirer.com.